Key Points
- Director Vicky Gregg sold 1,250 shares at an average price of $191.76 for a total of $239,700, reducing her ownership by 6.84% to 17,037 shares; the transaction was disclosed in an SEC filing.
- Quest Diagnostics beat Q3 estimates, reporting $2.60 EPS vs. $2.51 expected and $2.82B revenue vs. $2.73B, and set FY2025 guidance of $9.760–$9.840 EPS (analysts' consensus ~9.7 EPS).
- The company announced a quarterly dividend of $0.80 per share (annualized $3.20) with a yield of 1.7%, payable January 28 to shareholders of record on January 13.
Quest Diagnostics Incorporated (NYSE:DGX - Get Free Report) Director Vicky Gregg sold 1,250 shares of the business's stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total transaction of $239,700.00. Following the transaction, the director owned 17,037 shares in the company, valued at approximately $3,267,015.12. This trade represents a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Quest Diagnostics Trading Down 0.3%
NYSE:DGX opened at $189.18 on Friday. Quest Diagnostics Incorporated has a 52 week low of $148.70 and a 52 week high of $197.55. The firm has a 50-day moving average price of $184.28 and a two-hundred day moving average price of $179.05. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. The firm has a market cap of $21.04 billion, a price-to-earnings ratio of 22.20, a price-to-earnings-growth ratio of 2.31 and a beta of 0.58.
Quest Diagnostics (NYSE:DGX - Get Free Report) last released its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.09. The company had revenue of $2.82 billion during the quarter, compared to analyst estimates of $2.73 billion. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.Quest Diagnostics's quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.30 earnings per share. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. On average, equities analysts expect that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.
Quest Diagnostics Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 13th. Quest Diagnostics's payout ratio is presently 37.56%.
Analyst Ratings Changes
DGX has been the subject of several research reports. UBS Group increased their price target on shares of Quest Diagnostics from $180.00 to $190.00 and gave the company a "neutral" rating in a research report on Friday, October 17th. Leerink Partners increased their target price on shares of Quest Diagnostics from $203.00 to $210.00 and gave the company an "outperform" rating in a research report on Tuesday, October 21st. Piper Sandler raised their price target on shares of Quest Diagnostics from $190.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, October 27th. Morgan Stanley set a $207.00 price target on shares of Quest Diagnostics and gave the stock an "overweight" rating in a report on Wednesday, October 22nd. Finally, Wall Street Zen downgraded Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $196.31.
Check Out Our Latest Report on Quest Diagnostics
Hedge Funds Weigh In On Quest Diagnostics
Large investors have recently modified their holdings of the business. Boston Partners bought a new stake in shares of Quest Diagnostics in the first quarter valued at approximately $388,724,000. Norges Bank bought a new position in Quest Diagnostics in the 2nd quarter worth approximately $238,122,000. EdgePoint Investment Group Inc. grew its stake in Quest Diagnostics by 66,757.0% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 849,752 shares of the medical research company's stock valued at $161,946,000 after buying an additional 848,481 shares in the last quarter. M&G PLC grew its stake in Quest Diagnostics by 256.5% in the 2nd quarter. M&G PLC now owns 1,072,721 shares of the medical research company's stock valued at $193,090,000 after buying an additional 771,824 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Quest Diagnostics by 9.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,984,238 shares of the medical research company's stock valued at $1,012,534,000 after acquiring an additional 493,960 shares during the period. Hedge funds and other institutional investors own 88.06% of the company's stock.
About Quest Diagnostics
(
Get Free Report)
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
